Quintrio
Home

LABORATORY ANALYTICAL INSTRUMENTS

Agilent Technologies Inc.

A

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.

Last trade $172.28
Day change -$0.64 (-0.37%)
Day range $171.27 – $174.11
Volume 849,048
Market cap $48.75B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$48.75B
Price / earnings
33.85×
Price / book
6.62×
Price / sales
6.61×
EV / sales
6.91×
EV / EBITDA
26.67×

Profitability

Earnings per share
$5.11
Return on assets
10.31%
Return on equity
19.56%
Dividend yield
0.59%

Liquidity and leverage

Debt / equity
0.54×
Current ratio
2.05×
Quick ratio
1.56×
Cash ratio
0.77×

Cash flow

Price / cash flow
30.3×
Price / free cash flow
38.48×
Free cash flow
$1.27B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for A, quarterly periods
Line itemQ3 FY2026 Jul 31, 2026Q2 FY2026 Apr 30, 2026Q1 FY2026 Jan 31, 2026Q4 FY2025 Oct 31, 2025Q3 FY2025 Jul 31, 2025Q2 FY2025 Apr 30, 2025Q1 FY2025 Jan 31, 2025Q4 FY2024 Oct 31, 2024
Revenue$1.88B$1.84B$1.8B$1.86B$1.74B$1.67B$1.68B$1.7B
Cost of revenue$836M$845M$852M$871M$850M$802M$782M$785M
Gross profit$1.04B$990M$946M$990M$888M$866M$899M$916M
Selling, general and administrative$475M$465M$476M$428M$417M$454M$410M$397M
Research and development$123M$126M$117M$119M$111M$112M$113M$111M
Total operating expenses$598M$591M$593M$547M$528M$566M$523M$508M
Operating income$444M$399M$353M$443M$360M$300M$376M$408M
Interest expense-$29M-$25M-$25M-$27M-$28M-$29M-$28M-$32M
Income before taxes$444M$408M$364M$442M$366M$260M$367M$401M
Income taxes$82M$69M$59M$8M$30M$45M$49M$50M
Net income$362M$339M$305M$434M$336M$215M$318M$351M
Net income attributable to common shareholders$362M$339M$305M$434M$336M$215M$318M$351M
EBITDA$510M$466M$420M$514M$432M$373M$448M$477M
Basic earnings per share$1.28$1.20$1.08$1.54$1.18$0.75$1.12$1.24
Diluted earnings per share$1.28$1.20$1.07$1.53$1.18$0.75$1.11$1.23

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

NRx Pharmaceuticals, Inc. (NRXP) Reports Q3 Loss, Misses Revenue Estimates

NRx Pharmaceuticals reported a Q3 loss of $0.05 per share, beating expectations of $0.29 loss, but missed revenue estimates with $1.16 million versus consensus. The company received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revisions, and shares have underperformed the S&P 500 by 29.7% year-to-date.

Zacks Investment Research

Agilent Technologies (A) Reports Next Week: Wall Street Expects Earnings Growth

Agilent Technologies is expected to report Q4 2026 earnings on November 23, with consensus estimates of $1.72 EPS (up 8.2% YoY) and $1.98B in revenues (up 6.7% YoY). However, with a Zacks Rank of #4 and a modest Earnings ESP of +0.31%, the company is not considered a compelling earnings-beat candidate. While Agilent beat estimates by 9.46% in the last quarter, the current combination of metrics makes it difficult to predict an earnings surprise.

Zacks Investment Research

Aveanna Healthcare (AVAH) Q3 Earnings and Revenues Beat Estimates

Aveanna Healthcare reported Q3 2026 earnings of $0.23 per share, beating consensus estimates of $0.20, with revenues of $695.54 million exceeding expectations by 1.81%. The company has outperformed market estimates in four consecutive quarters and gained 60.2% year-to-date. Aveanna received a Zacks Rank #2 (Buy) rating with favorable estimate revision trends. Meanwhile, Agilent Technologies is expected to report Q3 2026 results on November 23, with projected earnings of $1.72 per share (+8.2% YoY) and revenues of $1.99 billion (+6.7% YoY), though consensus estimates were revised 1% lower in the last 30 days.

GlobeNewswire Inc.

Nucleic Acid Labeling - Global Strategic Business Report 2026: Secure Share of a $2.8 Billion Market by 2032 as Thermo Fisher Scientific, Roche, Merck, and Agilent Accelerate Genomics

The global nucleic acid labeling market is projected to grow from $1.7 billion in 2025 to $2.8 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in genomics, molecular diagnostics, NGS, and high-throughput laboratory workflows. Key applications include oligonucleotide labeling and in-situ hybridization, with the U.S. and China representing major regional markets.

Zacks Investment Research

ALGN Q3 Earnings & Revenues Beat, '26 Sales View Down, Stock Falls

Align Technology (ALGN) reported Q3 2026 earnings of $2.80 per share (up 7.3%) and revenues of $1.01 billion (up 1.9%), both beating estimates. Clear Aligner shipments grew 6.6% to a record level, supported by strong international growth and improved doctor utilization. However, Systems revenues declined 7.6% due to pricing pressure from lower-priced scanner configurations. The company cut its 2026 revenue guidance to $4.11-$4.13 billion, citing softer Systems and Services expectations and lower Clear Aligner ASP assumptions, causing shares to fall 0.7% after-hours.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Oct 6, 2026$0.255Oct 28, 2026recurring
Jun 30, 2026$0.255Jul 22, 2026recurring
Mar 31, 2026$0.255Apr 22, 2026recurring
Jan 6, 2026$0.255Jan 28, 2026recurring
Sep 30, 2025$0.248Oct 22, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 3, 20141,398-for-1,000forward split